Phase 3Completed
A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus
A Multicenter, Randomized, Open-label, and Parallel Assignment Phase III Study to Compare the Efficacy and Safety of Semaglutide Injection With Ozempic® in Combination With Metformin in the Treatment of Type 2 Diabetes
- Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd., (Industry)
- Enrolment
- 476 enrolled
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- semaglutide injection
- Ages
- adults, older adults
- Registry
- NCT05816057
Full record on ClinicalTrials.gov
From the registry
Semaglutide injection is a new drug developed according to Ozempic® biosimilars.This trial is conducted in China. The purpose of this study is to investigate the similarities in the efficacy and safety of semaglutide injection and Ozempic® in the treatment of type 2 diabetes, respectively.
Primary outcomes
- The observed mean change in Glycosylated Haemoglobin A1c (HbA1c) values from baseline after 32 weeks of treatment.
History
Last registry update
Study completion
Primary completion
Registered
Started
In the news
TrialsNature Medicine (opens Nature Medicine in a new tab)
Randomized trial investigates kidney protective mechanisms of semaglutide in type 2 diabetes
Researchers examined semaglutide in type 2 diabetes patients using histology, multiparametric MRI, and transcriptomics to understand renal protection.
